Evidence map›Paper›PMID 33351914›Full record

ArticleGlycobiology2021

O-Fucose and Fringe-modified NOTCH1 extracellular domain fragments as decoys to release niche-lodged hematopoietic progenitor cells.

Shuiliang Yu, Weihuan Wang, Marwah Albakri, Xiaoxing Yu, Gurnoor Majihail, Seunghwan Lim, Rachel K Lopilato, Atsuko Ito, John Letterio, Robert S Haltiwanger and 1 more

Open access · greenAbstract read
In one paragraph

Article in Glycobiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Shuiliang YuDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Weihuan WangDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Marwah AlbakriDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Xiaoxing YuBeachwood High School, Beachwood, OH 44122, USA.
Gurnoor MajihailHathaway Brown School, Shaker Heights, OH 44122, USA.
Seunghwan LimDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Rachel K LopilatoComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
Atsuko ItoComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
John LetterioDepartment of Pediatrics, Case Western Reserve University, Cleveland, OH 44106, USA.
Robert S HaltiwangerComplex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA.
Lan ZhouDepartment of Pathology, Case Western Reserve University, Cleveland, OH 44106, USA.
Case Western Reserve University · USUniversity of Georgia · USShaker Heights Public Library · US

Funding

O-Glycosylation of Epidermal Growth Factor-like MotifsR01GM061126 · NIGMS · UNIVERSITY OF GEORGIA · PI HALTIWANGER, ROBERT S. · 2001 to 2021
$9.1M
Targeting Notch2 in Hematopoietic Cell Therapy.R01HL103827 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHOU, LAN · 2012 to 2022
$4.3M
Hes1-loss promotes dysregulation of epithelial homeostasis and inflammation in a serrated adenocarcinoma modelR01CA222064 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZHOU, LAN · 2018 to 2022
$2.0M
Glycoscience Training ProgramT32GM107004 · NIGMS · UNIVERSITY OF GEORGIA · PI AMSTER, I JONATHAN, HALTIWANGER, ROBERT S. · 2014 to 2021
$1.3M
NCI NIH HHS R01 CA222064NHLBI NIH HHS R01 HL103827NIGMS NIH HHS R01 GM061126NIGMS NIH HHS T32 GM107004
6 · The paper itself

Abstract

Successful hematopoietic progenitor cell (HPC) transplant therapy is improved by mobilizing HPCs from the bone marrow niche in donors. Notch receptor-ligand interactions are known to retain HPCs in the bone marrow, and neutralizing antibodies against Notch ligands, Jagged-1 or Delta-like ligand (DLL4), or NOTCH2 receptor potentiates HPC mobilization. Notch-ligand interactions are dependent on posttranslational modification of Notch receptors with O-fucose and are modulated by Fringe-mediated extension of O-fucose moieties. We previously reported that O-fucosylglycans on Notch are required for Notch receptor-ligand engagement controlling hematopoietic stem cell quiescence and retention in the marrow niche. Here, we generated recombinant fragments of NOTCH1 or NOTCH2 extracellular domain carrying the core ligand-binding regions (EGF11-13) either as unmodified forms or as O-fucosylglycan-modified forms. We found that the addition of O-fucose monosaccharide or the Fringe-extended forms of O-fucose to EGF11-13 showed substantial increases in binding to DLL4. Furthermore, the O-fucose and Fringe-extended NOTCH1 EGF11-13 protein displayed much stronger binding to DLL4 than the NOTCH2 counterpart. When assessed in an in vitro 3D osteoblastic niche model, we showed that the Fringe-extended NOTCH1 EGF11-13 fragment effectively released lodged HPC cells with a higher potency than the NOTCH2 blocking antibody. We concluded that O-fucose and Fringe-modified NOTCH1 EGF11-13 protein can be utilized as effective decoys for stem cell niche localized ligands to potentiate HPC egress and improve HPC collection for hematopoietic cell therapy.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCalcium-Binding ProteinsCHO CellsCricetulusFucoseHEK293 CellsHematopoietic Stem CellsHumansReceptor, Notch1Receptor, Notch2Adaptor Proteins, Signal TransducingCalcium-Binding ProteinsDLL4 protein, humanFucoseNOTCH1 protein, humanNOTCH2 protein, humanReceptor, Notch1Receptor, Notch2decoyshematopoietic progenitor cellsNotchO-fucosylglycans

Identifiers

PMID33351914
PMCPMC8176772
OpenAlexW3114317002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.